Corticosteroids and Vertebral Trabecular Bone Quality in Women with Rheumatoid Arthritis.

Glucocorticoids (GCs) are frequently prescribed to control disease in Rheumatoid Arthritis (RA). However, long-term GC therapy with high daily doses is associated with bone involvement, which is considered the main extra-articular complication of RA. The trabecular bone score (TBS) has proven useful in assessing vertebral trabecular bone quality and fracture risk. To identify whether the long-term treatment of low doses of GCs are associated with low vertebral TBS in RA patients. A cross-sectional study, including 203 women with RA (ACR, 1987). Clinical, epidemiologic, and therapeutic variables were assessed. We identified the current daily dose, duration, and cumulative dose of GCs. Vertebral bone quality was assessed by TBS. Low vertebral trabecular bone quality was defined as TBS ≤ 1.300. Multivariate logistic regression analyses were used to identify risk factors of low TBS. Prevalence of low TBS in RA women was 52%. RA + low TBS were older (61.9 vs. 55.5, < 0.001) and had higher prevalence of menopause (90% vs. 75%, = 0.004), hypertension (50% vs. 34%, ≤ 0.02), and diabetes mellitus (13% vs. 4%, = 0.02). There were no associations between GC use, neither doses or cumulative doses, and TBS. Multivariate analyses showed the following: age (OR: 1.05, 95% CI: 1.02-1.08) and the presence of diabetes mellitus (OR: 3.30, 95% CI: 1.03-10.60) were associated with a high risk of low vertebral trabecular bone quality in RA. Half of the RA patients had low trabecular bone quality. Older age and diabetes mellitus are important risk factors for low trabecular bone quality in RA. These findings should give alert to early detection of low TBS, establishing strategies aimed at avoiding the consequences of this complication, including vertebral fractures.